Search Results - "Warrellow, Graham"

Refine Results
  1. 1

    Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx ® and Arcoxia by Caturla, Francisco, Amat, Mercè, Reinoso, Raquel F., Córdoba, Mónica, Warrellow, Graham

    Published in Bioorganic & medicinal chemistry letters (15-06-2006)
    “…The enantiomeric synthesis and profiling of sulfoxide-based rofecoxib and etoricoxib (Merck) prodrugs are reported. The preparation of the sulfoxide analogues…”
    Get full text
    Journal Article
  2. 2

    Squaric acid derivatives as VLA-4 integrin antagonists by PORTER, John R, ARCHIBALD, Sarah C, WARRELLOW, Graham J, ALEXANDER, Rikki P, LANGHAM, Barry, CHILDS, Kirstie, CRITCHLEY, David, HEAD, John C, LINSLEY, Janeen M, PARTON, Ted A. H, ROBINSON, Martyn K, SHOCK, Anthony, TAYLOR, Richard J

    Published in Bioorganic & medicinal chemistry letters (08-04-2002)
    “…SAR studies aimed at improving the rate of clearance by the incorporation of a 3,4-diamino-3-cyclobutene-1,2-dione group as an amino acid isostere in a series…”
    Get full text
    Journal Article
  3. 3

    Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists by Porter, John R., Archibald, Sarah C., Brown, Julien A., Childs, Kirstie, Critchley, David, Head, John C., Hutchinson, Brian, Parton, Ted A.H., Robinson, Martyn K., Shock, Anthony, Warrellow, Graham J., Zomaya, Alex

    Published in Bioorganic & medicinal chemistry letters (17-06-2002)
    “…SAR studies aimed at improving the rate of clearance of a series of VLA-4 integrin antagonists by the introduction of a 1,3,5-triazine as an amide isostere are…”
    Get full text
    Journal Article
  4. 4

    PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs by Hughes, Bernadette, Owens, Ray, Perry, Martin, Warrellow, Graham, Allen, Rodger

    Published in Drug discovery today (01-03-1997)
    “…Phosphodiesterase 4 (PDE 4) enzymes are the principal phosphodiesterases responsible for the hydrolysis of cAMP in pro-inflammatory leukocytes. The functional…”
    Get full text
    Journal Article
  5. 5

    Dehydrophenylalanine derivatives as VLA-4 integrin antagonists by Porter, John R., Archibald, Sarah C., Brown, Julien A., Childs, Kirstie, Critchley, David, Head, John C., Parton, Ted A.H., Robinson, Martyn K., Shock, Anthony, Taylor, Richard J., Warrellow, Graham J.

    Published in Bioorganic & medicinal chemistry letters (10-03-2003)
    “…We describe a series of dehydrophenylalanine derivatives where the Z isomers are potent VLA-4 antagonists but are subject to rapid biliary clearance and the E…”
    Get full text
    Journal Article
  6. 6

    N-(Pyrimidin-4-yl) and N-(Pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists by Porter, John R., Archibald, Sarah C., Brown, Julien A., Childs, Kirstie, Critchley, David, Head, John C., Hutchinson, Brian, Parton, Ted A.H., Robinson, Martyn K., Shock, Anthony, Warrellow, Graham J., Zomaya, Alex

    Published in Bioorganic & medicinal chemistry letters (17-06-2002)
    “…The SAR studies to optimise both potency and rate of clearance in the rat for a series of pyrimidine and pyridine based VLA-4 antagonists are described. A…”
    Get full text
    Journal Article
  7. 7

    Interview with Graham Warrellow by Isaac Bruce by Warrellow, Graham

    Published in Future medicinal chemistry (01-06-2012)
    “…Following his academic studies at the University of Surrey (UK), Graham Warrellow entered the pharmaceutical industry to pursue a career at the forefront of…”
    Get more information
    Journal Article
  8. 8
  9. 9

    Investigation of the in Vitro Metabolism Profile of a Phosphodiesterase-IV Inhibitor, CDP-840: Leading to Structural Optimization by Li, C, Chauret, N, Trimble, L A, Nicoll-Griffith, D A, Silva, J M, MacDonald, D, Perrier, H, Yergey, J A, Parton, T, Alexander, R P, Warrellow, G J

    Published in Drug metabolism and disposition (01-03-2001)
    “…CDP-840 is a selective and potent phosphodiesterase type IV inhibitor, whose in vitro metabolism profile was first investigated using liver microsomes from…”
    Get full text
    Journal Article
  10. 10

    Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors by Caturla, Francisco, Amat, Mercè, Reinoso, Raquel F., Calaf, Elena, Warrellow, Graham

    Published in Bioorganic & medicinal chemistry letters (01-07-2006)
    “…The enantiomeric synthesis and profiling of sulfoxide-based prodrugs of potent COX-2 inhibitors discovered at Almirall are reported. The preparation of the…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13

    Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx super([registered]) and Arcoxia super([registered]) by Caturla, Francisco, Amat, Merce, Reinoso, Raquel F, Cordoba, Monica, Warrellow, Graham

    Published in Bioorganic & medicinal chemistry letters (01-06-2006)
    “…The preparation of the sulfoxide analogues 2 and 4, and their enantiomeric pure forms is discussed as well as their potential to act as prodrugs to the potent…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Synthesis and structure-activity relationships of piperidinylpyrrolopyridine derivatives as potent and selective H1 antagonists by FONQUERNA, Silvia, MIRALPEIX, Montse, BELETA, Jorge, RYDER, Hamish, PAGES, Lluis, PUIG, Caries, CARDUS, Arantxa, ANTON, Francisca, VILELLA, Dolors, APARICI, Monica, PRIETO, José, WARRELLOW, Graham

    Published in Bioorganic & medicinal chemistry letters (15-02-2005)
    “…The synthesis and structure-activity relationships of piperidinylpyrrolopyridines as potent and selective H(1) antagonists are discussed. It was found that the…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20